Introduction
In many species, including man, the second most abundant lipid in lung surfactant is phosphatidylglycerol (PG) which may comprise 10% or more of the total lipid in surfactant from mature lungs [20] . Interest in surfactant PG was stimulated by the finding that surfactant obtained from tracheal aspirates of full-term infants contained significant amounts of PG while this lipid was absent from the surfactant of premature infants [13] . Infants delivered before their surfactant contained a large amount of PG were at greater risk of succumbing to hyaline membrane disease. During lung development in the human and in other species, the PG content of surfactant rises with a concomitant fall in phosphatidylinositol (PI) content. It has been proposed that the relative rates of synthesis of PI and PG for surfactant may be influenced by the availability of myo-inositol in the lung [3, 15] . In many tissues, the limited amount of CDP-diacylglycerol that is present likely restricts the biosynthesis of both PI and PG and it has been observed in vitro that the metabolic fate of CDPdiacylglycerol is influenced by the extracellular concentration of myo-inositol [8, 10, 11] . It .has been observed also that excess myo-inositol administered to adult rabbits decreased surfactant PG and increased surfactant PI [14] . We have examined previously myo-inositol homeostasis in the fetal rabbit [3] and in the human fetus [21] , Based on the results of those studies we concluded that lung development in the human and in the rabbit is accompanied by decreased availability of myo-inositol for surfactant PI biosynthesis. In addition, we observed that myo-inositol (in concentrations similar to those measured in vivo) affected the incorporation of { 14 C} glycerol into glycerophospholipids by fetal rabbit lung explants [18] and by type II pneumonocytes isolated from adult rat lung [4] . As the myo-inositol content of the culture medium was increased, PI biosynthesis was stimulated at the expense of PG biosynthesis. In the present investigation myo-inositol was administered chronically to nonpregnant rats and to pregnant rats and the effect of this treatment on the glycerophospholipid composition of lung tissue and lung lavage was measured. In addition, the influence of myo-inositol administration to pregnant rats on the glycerophospholipid composition of lung tissue of their fetuses was investigated.
Materials and methods
i Sprague-Dawley rats were purchased from HOLTZ-MAN (Madison, WI). The time of conception of the pregnant rats was known to within 12 hours. Throughout the experiment, the dams had free access to standard laboratory chow and drinking water. For 5 days before sacrifice, the dams received twice daily intraperitoneal injections of myo-inositol (180mg) (SIGMA, St. Louis, MO) or saline. The group of rats injected with myoinositol also had drinking water containing myoinositol (7% w/v.). Blood samples were obtained from the tail vein of the rats and processed for measurement of myo-inositol [3] . In experiments utilizing pregnant rats, the animals were sacrificed on day 18 or day 21 of gestation with a lethal dose of Nembutal. Fetuses were removed quickly and fetal blood was obtained from decapitated fetuses using a capillary pipette. Fetal lungs were removed and kept at 4°C until processed. In all studies, alveolar material was obtained from adult animals by lavaging the lungs with three 10ml aliquots of 0.9% NaCl via a tracheal cannula. The lungs were then dissected from the thorax and kept at 4°C until processed further. myo-inositol was measured in adult and fetal blood by gas-liquid chromatography of its trimethylsilyl (TMS) derivative as described previously [3] . The amount of TMS-myo-inositol in each extract was computed by measurement of peak area relative to the peak areas obtained with The values (Mean ± SE) for adult rats represent all measurements obtained on days 1,3, and 5 of treatment. The values (Mean ± SE) for fetuses represent pooled blood from littermates. Numbers in parentheses are number of determinations.
* .01 compared to saline treated pregnant rats ** .05 compared to saline treated day 21 fetuses known amounts of authentic TMS-myo-inositol (SIGMA). The values for serum myo-inositol concentration were corrected for total recovery of tracer myo-(2-3 H) inositol added to each initial extract. Total recovery of the myo<2-3 H) inositol throughout the procedure ranged between 67 and 75%. For determination of glycerophospholipid composition, lung lavage material was centrifuged (600 g χ 10 min) at 4 °C and lipids were extracted from the supernatant fluid and from lung tissue homogenates as described elsewhere [2] . Phospholipids were separated by 2-dimensional thin-layer chromatography [23] and areas of thin-layer chromatograms containing individual phospholipid classes were transferred to test tubes. Lipid phosphorus was measured as described by AMES and DUBIN [9] .
Results
The concentration of myo-inositol in the serum of pregnant rats was significantly higher than that in nonpregnant rats (p < .01). Treatment of the rats (pregnant and nonpregnant) with myo-inositol resulted in elevated serum concentrations of myoinositol throughout the 5 days of the experiment (Tab. I). Consistently, however, there was a tendency for the serum myo-inositol concentration in myo-inositol treated animals* to decrease over the course of the experiment (Fig. 1) . Between day 18 and day 21 of development, there was a significant decrease in serum myo-inositol concentrations in the fetuses of saline treated rats (p < .05). Treatment of the pregnant dams with myo-inositol resulted in a significant elevation in fetal serum concentrations of myo-inositol on both day 18 and day 21 of gestation. Interestingly, however, the concentration of myo-inositol in the serum of fetuses of rats that received myo-inositol was still greater on day 18 than on day 21, .and so was analogous to the normal decline observed in fetuses of the saline treated rats (Tab. I). After 5 days of myo-inositol administration, the glycerophospholipid composition of lung tissue and lavage was analyzed. In both pregnant and nonpregnant adult rats, there were significant decreases in the PG content of lung tissue (p<.02) and lung lavage material (p < .01). These decreases were associated with a significant increase in the PI content of lung tissue (p < .01) and of lung lavage material (p<.001). The phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine content of adult lung tissues and lung lavage material were not affected by myo-inositol administration (Tab. II). Although the administration of myo-inositol to adult rats resulted in a decrease in the PG content of their surfactant it did not appear to affect drastically the health of these animals. Nonpregnant adult rats treated with myoinositol had the same respiratory rate as the saline treated rats and they maintained normal body weight. Similarly, pregnant rats treated with myoinositol had normal respiratory rates, weight gains and litter sizes (data not shown). Having increased myo-inositol availability to the fetuses of pregnant rats treated with myo-inositol, the effect of this increased availability on the glycerophospholipid composition of developing fetal lung tissue was investigated. Between day 18 and day 21 of gestation, there was a significant increase (p < .05) in the PG content (expressed as percent of total glycerophospholipid) of lung tissue obtained from fetuses of the saline treated dams with a concomitant decrease in PI content (p < .05). Administration of myo-inositol to pregnant rats for five days resulted in a significant decrease in the PG content of fetal lung tissues at both day 18 (p < .05) and day 21 (p < .01) of gestation and a significant increase (p < .05) in the PI content of lung tissues of day 21 fetuses (Tab. HI), myo-inositol treatment had no effect on the phosphatidylcholine, phosphatidylserine or phosphatidylethanolamine content of fetal lung tissues at day 18 or day 21 of gestation. The effect of myo-inositol administration on glycerophospholipid compositions was most striking when the phosphatidylglycerol to phosphatidylinositol ratio (PG/PI ratio) of the different groups was compared (Fig. 2) . As expected, the PG/PI ratio of lung lavage material was much higher than The data are expressed as mole percent of total glycerophospholipid (Mean < SE). (* P < .02, ** p < .01, *** p < .001, when compared to rats treated with myo-inositol). Values for "other" phospholipids were calculated as the difference between the total amount of lipid phosphorus applied to the thin-layer chromatography plate and the amount recovered in the five glycerophospholipids listed above. The data are expressed as mole percent of total glycerophospholipid (Mean ± SE). (* p < .05 when compared to fetuses of mothers treated with myo-inositol). Values for "other" phospholipids were calculated as the difference between the total amount of lipid phosphorus applied to the thin-layer chromatography plate and the amount recovered in the five glycerophospholipids listed above.
that of lung tissue. Treatment with myo-inositol resulted in a highly significant (p < .001) decrease in the PG/PI ratio in both lung tissue and in lung lavage material of adult rats. The PG/PI ratio of fetal lung tissue increased normally between day 18 and day 21 of gestation (p<.05) but the administration of myo-inositol to pregnant rats prevented this normal developmental increase in the PG/PI ratio of lung tissues of their fetuses (p < .05). Although the phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine content of adult and fetal lung tissues and lung lavage material was unaffected by myo-inositol treatment, the PG/PI ratios of adult lung tissues, adult lung lavage, day 18 fetal lung tissues, and day 21 fetal lung tissues were all reduced to very similar low values.
Discussion
As part of an investigation 1 of the influence of myo-inositol on lung surfactant composition, pregnant and nonpregnant rats were treated with myoinositol. The concentration of myo-inositol in the serum of pregnant rats was significantly greater than that in the serum of nonpregnant rats. Possible explanations for this finding include increased myo-inositol biosynthesis in maternal tissues and decreased renal clearance of myoinositol by the maternal kidney. Increased synthesis is a likely possibility because myo-inositol synthesis in several adult rat tissues is known to be under hormonal control [17] . The putative rate limiting enzyme in myo-inositol biosynthesis is D-glucose 6-phosphate: 1 L-my o-inositol 1 -phosphate cyclase (cyclase) [9] . In the rat, cyclase activity in primary and secondary sex organs is regulated by pituitary hormones whereas cyclase activity in the liver is regulated by thyroid hor-mones [17] . It is possible that gonadotropic studies involved short-term infusion of myohormones synthesized during pregnancy might inositol. If the bulk of the administered myoexert an effect similar to that of pituitary hor-inositol is rapidly cleared from the maternal mones.
circulation by the kidneys, there may be only In both pregnant and nonpregnant rats, treatment limited exposure of the fetus to high concentrawith myo-inositol resulted in a marked increase in tions of myo-inositol. If the rate of uptake of serum myo-inositol concentrations. Over the myo-inositol by the placenta is slow, a rather long course of the 5 day treatment period, however, the exposure to large amounts of myo-inositol may high concentration of myo-inositol in the serum of be required before a significant change in the treated rats consistently declined toward normal, concentration of myo-inositol in fetal serum is This may reflect altered renal metabolism or observed. clearance of myo-inositol since in man at least, the It has been reported previously that the phoskidney is the major regulator of serum myo-phatidylethanolamine content of adult rat lung inositol [7] . The human kidney both synthesizes tissue is greater than that reported here [22] . and oxidizes large amounts of myo-inositol and An explanation for this difference may be that the rate of oxidation of myo-inositol appears to ethanolamine plasmalogen which co-chromatodepend upon the plasma concentration of myo-graphs with phosphatidylethanolamine in most inositol and renal plasma flow [7] .
thin-layer Chromatographie systems may have been The finding that the concentration of myo-inositol included with the total phosphatidylethanolamine in fetal rat serum decreases between day 18 and measured in previous investigations. In the present day 21 is consistent with previous observations in investigation, however, the acidic extraction conthe rabbit [3] and in man [21] and is compatible ditions that were employed resulted in the hydrowith the proposition that late in gestation there is lysis of ethanolamine plasmalogen and so it would a decreasing availability of myo-inositol for PI not have contributed to the measured amounts of biosynthesis in fetal rat lung, myo-inositol avail-phosphatidylethanolamine [16] . ability to the fetal lung may therefore be an The presence of myo-inositol in increased concenimportant regulator of the developmental change trations in maternal and fetal rat serum resulted in from the production of a surfactant rich in PI to a significantly reduced PG/PI ratio in lung tissue one rich in PG. The present observation that the m & i ung i avage material without affecting the concentration of myo-inositol in fetal rat serum amount of phosphatidylcholine, phosphatidyldeclines at a time when the PG content of lung serine or phosphatidylethanolamine present. This tissue increases is consistent with such a view, finding extends the previous observation that myoSimilar changes in the extracellular concentration inositol administration to nonpregnant adult of myo-inositol were found to affect the relative ra bbits resulted in a decreased PG/PI ratio in lung rates of synthesis of PI and PG by rat type II i avage material from adult lungs [14] . A reciprocal pneumonocytes in vitro [4] .
relationship between the synthesis of PG and that Treatment of pregnant rats with myo-inositol of PI has been observed in several tissues [8, 11] effected a significant elevation in myo-inositol and likely reflects competition for the limited concentration in the serum of their fetuses at both amount of CDP-diacylglycerol that is the common day 18 and day 21 of gestation. This most likely precursor of both these glycerophospholipids. reflects transplacental uptake of myo-inositol Competition for CDP-diacylglycerol appears to be although in previous studies employing sheep, no influenced by the availability of myo-inositol such transplacental transport of -myo-inositol to the that an increase in the extracellular concentration fetus could be detected when a large amount of of myo-inositol results in the stimulation of PI biomyo-inositol was administered in a single intra-synthesis at the expense of PG biosynthesis, venous injection to the pregnant ewe [5, 19] . In In the present investigation, increasing myoaddition to species differences, there are other inositol availability to the fetus prevented the propossible reasons for this discrepancy. Previous duction of a surfactant characteristic of mature lungs, i.e., one rich in PG. This finding is compatible with the observation that PI synthesis is favored over that of PG in rat type II pneunionocytes in vitro when the extracellular concentration of myo-inositol exceeds 300 μιη [4] . Although that investigation was performed employing type II pneumonocytes isolated from adult rats, it was shown in another investigation that, at least in the rabbit, the characteristics of myo-inositol uptake by slices of adult and fetal lung are very similar [3] . The present findings also complement the observation that when insulin was infused into pregnant rabbits the concentrations of glucose, insulin, and myo-inositol in fetal serum were decreased in association with the production by the fetus of a lung surfactant enriched in PG [15] . We speculate that myo-inositol may be involved also in the delayed appearance of PG in the lung surfactant of the human fetus in pregnancies complicated by diabetes mellitus. Patients with diabetes mellitus are know to have myo-inositol intolerance [6] and this has been implicated in the etiology of diabetic neuropathy [12] . This intolerance is corrected by insulin therapy [6] . The imbalance in myo-inositol homeostasis in the pregnant diabetic woman might affect adversely myoinositol homeostasis in her fetus. Specifically, increased placental transfer of myo-inositol (resulting from high concentrations of myoinositol in maternal blood) and/or increased synthesis de novo by the fetus (supported by increased glucose availability to the fetus) might result in a delay in the appearance of a lung surfactant enriched with PG. The results of this investigation support the hypothesis that factors which affect myo-inositol homeostasis result in an altered glycerophospholipid composition of surfactant in adults and fetuses and justify an examination of myo-inositol homeostasis in human pregnancies complicated by diabetes mellitus.
Summary
In many species including man, the second most abundant lipid in lung surfactant is phosphatidylglycerol (PG) which may comprise 10% of the total lipid in surfactant from mature lungs. Infants delivered before their surfactant contained a large amount of PG are at greater risk of succumbing to hyaline membrane disease. Regulation of the PG content of lung surfactant is not understood completely, but the reciprocal changes in the amount of phosphatidylinositol (PI) and PG in surfactant as the lung mature are suggestive of regulation at the level of a common precursor. The immediate common precursor of PI and PG is CDPdiacylglycerol which is found in only small amounts in most mammalian cells and likely restricts the biosynthesis of both PI and PG. It has been observed in several species that the enzymes that synthesize PI and PG compete for the limited amount of CPD-diacylglycerol and this competition is influenced by the availability of myo-inositol. We and others have presented evidence that myo-inositol availability in the developing lung may be an important factor in the regulation of lung surfactant composition. In the present investigation, myo-inositol was administered chronically to nonpregnant and to pregnant rats and the effect of this treatment on the glycerophospholipid composition of lung tissue and lung lavage was measured. In addition, the influence of myo-inositol administration to pregnant rats on the glycerophospholipid composition of lung tissue of their fetuses was investigated. The concentration of myo-inositol in adult and fetal blood was measured by gas-liquid chromatography of its trimethylsilyl derivative. For determination of glycerophospholipid composition, the total lipid extracts of lung tissues and lung lavage were separated by 2-dimensional thin-layer chromatography and quantified by lipid phosphorus assay of individual spots. The concentration of myo-inositol in the serum of pregnant rats was significantly higher than in nonpregnant rats (Tab. I, Fig. 1) . Treatment of the rats with myo-inositol resulted in a significant elevation of serum concentrations of myo-inositol throughout the experimental period. Between day 18 and day 21 of the gestation there was a significant decrease in serum myo-inositol concentrations in fetuses of saline treated rats. Treatment of the pregnant dams with myo-inositol resulted in a significant elevation in fetal serum concentrations of myo-inositol on both day 18 and day 21 of gestation (Tab. I). After 5 days of myo-inositol administration, the glycerophospholipid composition of lung tissue and lung lavage was analyzed. In both pregnant and nonpregnant rats, there was a significant decrease in the PG content of lung tissue (p < .02) and lung lavage material (p < .01) associated with a significant increase in their PI content (p < .01 and ρ < .001, respectively). The content of other measured glycerophospholipids was unaffected by treatment (Tab. II). Between day 18 and day 21 of gestation, there was significant increase (p < .05) in the PG content with a concomitant decrease in PI content (p < .05) of lung tissue obtained from fetuses of saline treated dams. Administration of myo-inositol to pregnant rats resulted in a significant decrease in the PG content of fetal lung tissue on day 18 (p < .05) and day 21 (p < .01) and a significant increase (p < .05) in the PI content of lung tissue of day 21 fetuses (Tab. III). The PG/PI ratio of the various groups were compared. The ratio, as expected, was much higher for lung lavage material than lung tissue in the adult rats. Similarly, the PG/PI ratio in fetal lung tissue was higher on day 21 than on day 18 of gestation. Following myo-inositol treatment, the PG/PI ratio of adult lung tissue, adult lung lavage, day 18 fetal lung tissue and day 21 fetal lung tissue were all reduced to very similar ratios (Fig. 2) . These findings extend previous observations that myoinositol affects the PG and PI content of lung lavage material. Competition for CDP-diacylglycerol appears to be influenced by the availability of myo-inositol such that an increased extracellular concentration of myoinositol results in the simulation of PI biosynthesis at the expense of PG biosynthesis. We speculate that myoinositol may be involved in the delayed appearance of PG in the lung surfactant of the human fetus in pregnancies complicated by diabetes mellitus. Patients with diabetes are known to have myo-inositol intolerance that is corrected by insulin therapy. Increased placental transfer of myo-inositol (from high maternal blood concentrations) and/or increased synthesis de novo by the fetus (supported by increased glucose availability) might result in a delay in the appearance of a lung surfactant enriched in PG.
Keywords: Fetal lung tissue, glycerophospholipids, myo-inositol, phosphatidylglycerol, phosphatidylinositol, rat lungs lavage. Fig. 1 ). Le traitement des rattes avec du myo-inositol entraine une elevation significative des concentrations seriques de myo-inositol tout au long de Pexperimentation. Entre le 18eme jour et le 21eme jour de la gestation, il y a une diminution significative des concentrations de myo-inositol serique chez les foetus de rattes traitees par du serum sale. Le traitement des meres gravides par myo-inositol entraine une elevation significative des concentrations foetales seriques de myoinositol ä la fois au ISeme et au 21eme jour de gestation (Tab. I). Au bout de 5 jours d'administration de myo-inositol, nous avons analyse la composition des glycerophospholipides des poumons et des liquides de lavage pulmonaire. Et chez le rattes gravides et chez les rattes non gravides, il y a une diminution significative de la teneur en PG des poumons (p < 0,02) et des produits de lavage pulmonaire (p < 0,01). Cette diminution est associee ä une augmentation significative de leur teneur en PI (p < 0,01 et p < 0,001, respectivement). La teneur des autres glycerophospholipides mesures n'a pas ete modifiee par le traitement (Tab. II). Entre le l Seme et le 21eme jour de gestation, il y a une augmentation significative (p < 0,05) de la teneur en PG avec une diminution concomittante de la teneur en PI (p < 0,05) dans les poumons des foetus dont les meres avaient ete traitees par du serum sale. L'administration de myo-inositol aux rattes gravides entraine une diminution significative de la teneur en PG des poumons foetaux a J 18 (p < 0,05) et ä J 21 (p < 0,01) ainsi qu'une augmentation significative (p < 0,05) de la teneur en PI des poumons des foetus ä J 21 (Tab. III). On a compare les rapports PG/PI des differents groupes. Comme on s'y attendait, le rapport est plus eleve chez le rat adulte dans les produits de lavage pulmonaire que dans les poumons. De faqon similaire, le rapport PG/PI dans les poumons adultes, dans les produits de lavage chez Padulte, et dans les poumons foetaux ä J 18 et ä J 21 sont tous diminues dans les proportions similaires (Fig. 2) . Ces donnees prolongent les observations anterieures qui demontraient que le myo-inositol agit sur la teneur en PG et PI du produit de lavage pulmonaire. La competition pour le CDP-diacylglycerol apparait comme influencee par la disponibilite du myo-inositol de teile sorte qu'une elevation de la concentration extra-cellulaire de myoinositol entraine la stimulation de la bio-synthese de PI au detriment de la bio-synthese de PG. Nous speculons que peut impliquer le myo-inositol dans Fapparition retardee du PG dans le surfactant pulmonaire du foetus
